Emerging transporters of clinical importance: an update from the International Transporter Consortium.
about
Structural basis for polyspecificity in the POT family of proton-coupled oligopeptide transportersRenal drug transporters and their significance in drug-drug interactionsRecent advances in understanding hepatic drug transportP-Glycoprotein Transport of Neurotoxic PesticidesComplementation of the Yeast Model System Reveals that Caenorhabditis elegans OCT-1 Is a Functional Transporter of AnthracyclinesThe Effect of Albumin on MRP2 and BCRP in the Vesicular Transport AssayApproaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites.Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion.ABCC5 transporter is a novel type 2 diabetes susceptibility gene in European and African American populations.Genetic factors affecting drug disposition in Asian cancer patients.Thermodynamic evidence for a dual transport mechanism in a POT peptide transporterOrganic cation transporter variation and response to smoking cessation therapiesExploring the structure-activity relationships of ABCC2 modulators using a screening approach.Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes.Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 ProteinsComparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication.A structure-activity relationship study of ABCC2 inhibitors.Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins.The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersRifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4).Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues.Stereoselectivity of chiral drug transport: a focus on enantiomer-transporter interaction.Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.Hepatic drug transporters: the journey so far.Transporter assays as useful in vitro tools in drug discovery and development.Exploring the Carbamazepine Interaction with Human Pregnane X Receptor and Effect on ABCC2 Using in Vitro and in Silico Approach.Computational modeling to predict the functions and impact of drug transporters.The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine.
P2860
Q27684288-7CAC2F0C-4B75-4415-84A8-312B334F0B8CQ28071292-D3F1A323-CC80-42BD-890E-69EA10F8B9C3Q28077066-E7B4B7AE-3921-4885-869E-E3D1362029D3Q28389145-FCB6133A-026B-4D7D-9411-1A9455C142F4Q28546572-CAEBCEEC-341B-4D33-8A80-9E20AAFF8E68Q28554497-4D805A73-D1A0-4788-BBFD-7E5790BD86B2Q30244676-7B701612-2565-4C3D-A333-98FBCBA3586FQ33742713-D3CD0D19-8A79-4DD4-BCA0-2336A05B5C76Q34235548-E797EC5A-C85F-47CD-BB59-7E7F6DBEC4ABQ34501025-F82AB449-BF00-4B61-AE26-7E414A51617BQ34737607-7912A11C-6975-4021-8780-4F80C1D30C9FQ34974830-2327741F-BC8B-403C-BDF4-AA8C043F829CQ35620872-1F8287D3-56FE-404B-9216-45BA16B38B58Q35768413-B63A46AE-972B-4033-9688-499C2C40E4AFQ35795744-3AA3ED17-67AE-470C-84A5-3280C85F6F11Q36093125-69892866-0EFF-41E0-9E32-FE1754E08FFDQ36276676-0B97D1AC-3161-44F5-B88E-F5CD98095ECBQ36316489-B8269A8C-CBC8-4963-84B4-3C5A232396B9Q36689589-49A3E162-E315-4197-8181-E4300500F750Q36835708-F49D02C1-2923-4655-B6D5-F1369EAD7426Q36924379-65AF1E23-6385-4F5D-A720-541B37AA9841Q37220775-B0FF29CA-4BBC-4AC0-A6D8-ECE7A8780BCFQ37394474-0D3391B1-0D5F-438B-93A6-D7E041E624E4Q37399109-B6F5B135-CACA-46AB-A173-3A51A1708124Q37550693-8BE38AEB-1C8F-4A8D-84AB-E15ED2F23767Q37607930-9A0E46BE-6343-4CE6-9FEA-BDAB95BA5116Q38099195-7963A54A-3172-4F44-975D-9604C5566203Q38200490-46A56B83-B0F6-4317-BA62-018787728C64Q38209395-1028B575-ED01-40A1-945A-8E7515BA4A32Q38324557-02D8AB75-D3E4-40EE-8CE8-CA38798DA49FQ38379295-77C2925D-D66B-47CB-BE8B-B2D0EB540C04Q38478413-7F51DB02-0CC2-411F-B97A-7C4301CE1BD9Q38560889-D527116D-0C6A-4CD0-8656-08F73893091AQ38619057-2015A4B6-0531-4E81-AD07-AFA565ECE44FQ38706504-BD103FC7-C70C-4841-9304-92B3D03B05EFQ38715008-F6E587CB-A67C-4148-B2A3-A2F15136F43FQ38716267-9DF2C2C9-7CD3-4E2D-A802-0BFDCB9CFA9DQ38750759-A5BC96C6-0C4C-4F80-A0F4-DF3333B54E9BQ38800092-18CD382F-5C29-4BF6-90AF-F3BBE7CCAE03Q38831370-6711756E-074F-413B-86C7-1168AD1B64D0
P2860
Emerging transporters of clinical importance: an update from the International Transporter Consortium.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging transporters of clini ...... tional Transporter Consortium.
@en
type
label
Emerging transporters of clini ...... tional Transporter Consortium.
@en
prefLabel
Emerging transporters of clini ...... tional Transporter Consortium.
@en
P2093
P2860
P356
P1476
Emerging transporters of clini ...... tional Transporter Consortium.
@en
P2093
International Transporter Consortium
K M Giacomini
K M Hillgren
P2860
P356
10.1038/CLPT.2013.74
P407
P577
2013-04-08T00:00:00Z